Skip to content
Belinostat
Beleodaq (belinostat) is a small molecule pharmaceutical. Belinostat was first approved as Beleodaq on 2014-07-03. It is used to treat t-cell lymphoma peripheral in the USA. It is known to target histone deacetylase 3, histone deacetylase 5, histone deacetylase 7, histone deacetylase 4, histone deacetylase 9, histone deacetylase 8, histone deacetylase 1, histone deacetylase 2, and histone deacetylase 6.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Beleodaq
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Belinostat
Tradename
Company
Number
Date
Products
BELEODAQAcrotech BiopharmaN-206256 RX2014-07-03
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
beleodaqNew Drug Application2022-03-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
t-cell lymphoma peripheral—D016411C84.9
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Belinostat, Beleodaq, Acrotech Biopharma
88355012027-10-27DP
68880272026-08-10DS, DPU-1544
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XH: Histone deacetylase (hdac) inhibitors
— L01XH04: Belinostat
HCPCS
Code
Description
J9032
Injection, belinostat, 10 mg
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic footD017719EFO_1001459123—49
Varicose ulcerD0146472—1——3
Diabetic neuropathiesD003929EFO_1000783——1—12
Foot ulcerD016523——1—12
UlcerD014456MPATH_579——1——1
Skin ulcerD012883HP_0200042L98.4——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular degenerationD008268EFO_0001365H35.30—1———1
Tennis elbowD013716EFO_1001896M77.1—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes mellitusD003920EFO_0000400E08-E13————22
PeriodontitisD010518EFO_0000649K05.3————11
NeoplasmsD009369C80————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBELINOSTAT
INNbelinostat
Description
Belinostat is a hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. It has a role as an antineoplastic agent and an EC 3.5.1.98 (histone deacetylase) inhibitor. It is a hydroxamic acid, a sulfonamide and an olefinic compound.
Classification
Small molecule
Drug classenzyme inhibitors: histone deacetylase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO
Identifiers
PDB5EEN
CAS-ID414864-00-9
RxCUI1543543
ChEMBL IDCHEMBL408513
ChEBI ID61076
PubChem CID6918638
DrugBankDB05015
UNII IDF4H96P17NZ (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
HDAC3
HDAC3
HDAC5
HDAC5
HDAC7
HDAC7
HDAC4
HDAC4
HDAC9
HDAC9
HDAC8
HDAC8
HDAC1
HDAC1
HDAC2
HDAC2
HDAC6
HDAC6
Organism
Homo sapiens
Gene name
HDAC3
Gene synonyms
NCBI Gene ID
8841
Protein name
histone deacetylase 3
Protein synonyms
Protein deacetylase HDAC3, Protein deacylase HDAC3, RPD3-2, SMAP45
Uniprot ID
Q9UEV0
Mouse ortholog
Hdac3 (15183)
histone deacetylase 3 (Q3UM33)
Variants
Clinical Variant
No data
Financial
Beleodaq - Spectrum Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,689 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,095 adverse events reported
View more details